Development
Dyne Therapeutics, Inc.
DYN
$10.47
$0.222.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.16% | -7.71% | 24.87% | 5.05% | -27.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.61% | 47.29% | 26.50% | 27.05% | -22.74% |
| Operating Income | -68.61% | -47.29% | -26.50% | -27.05% | 22.74% |
| Income Before Tax | -71.63% | -45.49% | -24.09% | -24.18% | 25.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.63% | -45.49% | -24.09% | -24.18% | 25.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.63% | -45.49% | -24.09% | -24.18% | 25.02% |
| EBIT | -68.61% | -47.29% | -26.50% | -27.05% | 22.74% |
| EBITDA | -69.31% | -47.66% | -26.79% | -27.42% | 23.01% |
| EPS Basic | -47.65% | -23.32% | -7.17% | -13.76% | 26.83% |
| Normalized Basic EPS | -47.63% | -23.33% | -7.14% | -13.82% | 26.82% |
| EPS Diluted | -47.65% | -23.32% | -7.17% | -13.76% | 26.83% |
| Normalized Diluted EPS | -47.63% | -23.33% | -7.14% | -13.82% | 26.82% |
| Average Basic Shares Outstanding | 16.24% | 17.98% | 15.78% | 9.16% | 2.47% |
| Average Diluted Shares Outstanding | 16.24% | 17.98% | 15.78% | 9.16% | 2.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |